Patricia Dudley, MD
Psychiatry · Meridian, MSNPI 1124234307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 30.7% of the total. Reporting peaked in 2021 at $613 and has fallen 75.4% since, to $151 in 2025.
Across 108 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$604
- Takeda Pharmaceuticals U.S.A., Inc.$313
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
- Otsuka America Pharmaceutical, Inc.$246
- Vanda Pharmaceuticals Inc.$205
- Lundbeck LLC$108
- plus $222 from 6 others
What the payments were for
- Food & beverage$1,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $604 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $313 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $270 |
| Otsuka America Pharmaceutical, Inc. | 15 | $246 |
| Vanda Pharmaceuticals Inc. | 7 | $205 |
| Lundbeck LLC | 5 | $108 |
| Sunovion Pharmaceuticals Inc. | 5 | $87 |
| Shire North American Group Inc | 3 | $51 |
| Neuronetics, Inc. | 1 | $26 |
| Alkermes, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$1,968 in reported general payments places this provider in the 70th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clorazepate Dipotassium | 24 | $1,418 |
| Duloxetine Hcl | 45 | $1,319 |
| Aripiprazole | 68 | $1,130 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $1,018 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 35 | $1,004 |
| Bupropion XlBupropion Hcl | 65 | $991 |
| Doxepin Hcl | 16 | $876 |
| Trazodone Hcl | 69 | $642 |
| Quetiapine Fumarate | 72 | $633 |
| Sertraline Hcl | 64 | $456 |
| Olanzapine | 22 | $454 |
| Lorazepam | 59 | $314 |
| Hydroxyzine Pamoate | 21 | $308 |
| Risperidone | 25 | $278 |
| Dexmethylphenidate Hcl | 11 | $276 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Meridian
- Kim NagelMeridian$5K
- Terry JordanMeridian$5K
- Ruben CruzMeridian$4K
- William TouchstoneMeridian$4K
- Mary LarkinMeridian$2K
- Maxie GordonClinton$1.3M
- Kurt BuechlerRidgeland$1.1M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.